NCT04955834招募中3 期
A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study to Compare the Efficacy and Safety of Insulin Degludec Injection Versus Tresiba® in Subjects With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 344
- 试验地点
- 2
- 主要终点
- Change value of glycosylated hemoglobin (HbA1c)
研究概览
简要总结
This study is a multi-center, randomized, open-label, parallel, positive-controlled registered clinical study,to evaluate the efficacy and safety of insulin degludec injection developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes (diagnosed clinically) for at least 6 months.
- •Aged ≥18 and ≤70 years old, male or female.
- •Subjects who were treated with a stable dose of oral hypoglycemic agents for more than 3 months before the random visit.
- •HbA1c is in the range of 7.5% -11.0 % by local laboratory analysis.
- •Body mass index (BMI) ≥18 kg/m2 and ≤40kg/m
- •Patients must give informed consent to this study before the trial, and voluntarily sign an informed consent form.
- •Patients who can communicate well with the investigator and can complete the study in accordance with the research regulations.
排除标准
- •Diagnosed as type 1 diabetes or other types of diabetes.
- •Patients who have received insulin therapy for more than 7 days within 3 months before screening .
- •Patients who have received a thiazolidinedione (TZD) or GLP-1 receptor agonist within 3 months before screening.
- •Patients who are receiving or have received chronic (lasting more than 2 weeks) systemic glucocorticoid therapy (excluding topical drugs and inhaled preparations) within 3 months before the random visit.
- •Patients who are receiving or have received chronic (lasting more than 2 weeks) systemic glucocorticoid therapy (excluding topical drugs and inhaled preparations) within 3 months before the random visit.
- •Patients with hypoglycemia who have recurring severe events with conscious and/or physical changes within 3 months before screening and need help from others.
- •Those who have experienced acute metabolic complications (ketoacidosis, lactic acidosis, or hyperosmolar coma, etc.) within 3 months before screening.
- •Patients with obvious liver and kidney dysfunction.
- •Hemoglobin <100g/L.
- •When the virological test during the screening period shows that any of the following is met:
- •(1) HCV（hepatitis C virus） antibody is positive, and the HCV virus titer test value exceeds the upper limit of normal value; (2) HBsAg（Hepatitis B surface antigen） is positive and the HBV（hepatitis B virus） DNA test value exceeds the upper limit of normal; (3) HIV（human immunodeficiency virus） positive; (4) Active syphilis;
- •At the time of screening, there are thyroid diseases that have not been controlled with stable doses of drugs within 6 months, and the results of thyroid function tests during the screening period are abnormal and have clinical significance.
- •Uncontrolled or poorly treated high blood pressure.
- •Those with decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, cardiac surgery or blood vessel reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) occurred within 6 months before screening.
- •Those with proliferative retinopathy or macular degeneration (macular edema) that requires urgent treatment during screening.
- •Once diagnosed as malignant tumor (except for basal cell carcinoma or squamous cell skin cancer).
- •Patients with severe chronic gastrointestinal diseases (such as active peptic ulcer) and severe infections.
- •Those who are allergic to any ingredient in insulin deglu injection and Novota®.
- •18.Those who participated in any other clinical trials within 3 months before screening (excluding those who failed the screening or did not use study drugs for other reasons).
- •Pregnant women, lactating women, women of childbearing age who do not take appropriate contraceptive measures during the trial period (sterilization, intrauterine device, oral contraceptives or barrier contraception).
- •Those who are judged by the investigator to be unsuitable to participate in the trial.
研究组 & 干预措施
Insulin degludec injection
Experimental
Insulin degludec injection subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
干预措施: Insulin degludec injection (Drug)
Tresiba®
Active Comparator
Insulin degludec injection（Tresiba®）subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
干预措施: Tresiba® (Drug)
结局指标
主要结局
Change value of glycosylated hemoglobin (HbA1c)
时间窗: Baseline and 26 weeks
Change value of HbA1c from baseline following 26 weeks of therapy
次要结局
- Percentage of patients achieving HbA1c ≤7% or HbA1c ≤6.5%(Baseline, week 26)
- Change value of fasting blood glucose(Baseline, week 14, week 26)
- Hypoglycemia(Baseline to week 26)
- Immunogenicity(Baseline, week 14, week 26)
- Change value of HbA1c(Baseline, week 14)
- Adverse events (AEs) and serious adverse events (SAEs)(Baseline to week 26)
- Abnormal findings(Baseline to week 26)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)NCT01659775LG Life Sciences389
已完成
4 期
Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and IrbesartanType 2 Diabetic NephropathyNCT03147677The Third Xiangya Hospital of Central South University60
尚未招募
3 期
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsObesityNCT06738979Chia Tai Tianqing Pharmaceutical Group Co., Ltd.408
招募中
3 期
Study of LY01610 in Patients With Recurrent Small Cell Lung CancerRelapsed Small Cell Lung CancerNCT06128837Luye Pharma Group Ltd.686
尚未招募
4 期
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisBreast Cancer Stage IVNCT05860907Fudan University384